Corcept Therapeutics
CORT
110 hedge funds and large institutions have $307M invested in Corcept Therapeutics in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 50 increasing their positions, 20 reducing their positions, and 13 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 20
23% more capital invested
Capital invested by funds: $250M → $307M (+$57.1M)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
1% more funds holding
Funds holding: 109 → 110 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.45M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$1.18M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$1.03M |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$945K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.34M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
-$3.25M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$824K |
| 4 |
First Eagle Investment Management
New York
|
-$575K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$561K |
CORT Hedge Fund Activity: Q3 2016 in Review
110 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2016, worth a combined $307M — up 23% from $250M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CORT positions and 13 closed out — a net gain of 1 holder — while 50 added to existing stakes and 20 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.45M. The largest seller was Morgan Stanley, cutting an estimated $3.34M.
- 110 institutional investors held Corcept Therapeutics (CORT) as of Q3 2016, up from 109 in Q2 2016.
- Funds reported $307M of Corcept Therapeutics stock for Q3 2016, up 23% quarter-over-quarter.
- 14 funds opened new Corcept Therapeutics positions in Q3 2016 and 13 closed out, a net change of +1 holder.
- The largest Corcept Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $1.45M added.
- The largest Corcept Therapeutics seller in Q3 2016 was Morgan Stanley, an estimated $3.34M sold.
Based on aggregated 13F filings for Q3 2016.